Circulating tumor DNA (ctDNA) is an emerging, multifaceted biomarker for predicting outcomes in B-cell non-Hodgkin lymphomas (B-NHL) following CD19-directed CAR-T therapy. This evidence concerns the gene CD19 and neoplasm.